External Beam Radiotherapy

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 11421 Experts worldwide ranked by ideXlab platform

Eric A Klein - One of the best experts on this subject based on the ideXlab platform.

  • monotherapy for stage t1 t2 prostate cancer radical prostatectomy External Beam Radiotherapy or permanent seed implantation
    Radiotherapy and Oncology, 2004
    Co-Authors: Louis Potters, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Eric A Klein, Michael W Kattan, Patrick A Kupelian
    Abstract:

    Abstract Background and Purpose To review the freedom from biochemical recurrence (FBR) rates after permanent prostate brachytherapy (PPB), External Beam Radiotherapy (RT) to a minimum 70Gy, or radical prostatectomy (RP) for clinically localized stage T1–T2 adenocarcinoma of the prostate. Patients and Methods The study cohort consisted of 1819 consecutively treated clinical stage T1–T2 (AJCC 1997) localized prostate cancer patients between 1992 and 1998. All patients received monotherapy treatment without additional adjuvant therapy. The distribution by treatment modality was as follows: RT for 340, RP for 746, and PPB for 733 cases. The median follow-up time was 58 months for all cases (51 months for PPB cases, 56 months for RT cases, and 64 months for RP cases). Biochemical relapse was defined as to be detectable PSA levels in RP cases, and the ASTRO consensus panel definition for the RT and PPB cases. Results The 7-year FBR rates for PPB vs EBRT vs RP were 74, 77, and 79%, respectively. Multivariate analysis identified iPSA ( P P Conclusions Pretreatment PSA levels, and biopsy Gleason score determined outcome in this study cohort. Biochemical failure rates in this study cohort are similar between PPB, RT, and RP as monotherapy for clinically localized prostate cancer.

  • clinical investigation prostateradical prostatectomy External Beam Radiotherapy 72 gy External Beam Radiotherapy 72 gy permanent seed implantation or combined seeds External Beam Radiotherapy for stage t1 t2 prostate cancer
    International Journal of Radiation Oncology Biology Physics, 2004
    Co-Authors: Patrick A Kupelian, Louis Potters, Deepak Khuntia, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Thomas P Carlson, Eric A Klein
    Abstract:

    Purpose To review the biochemical relapse-free survival (bRFS) rates after treatment with permanent seed implantation (PI), External Beam Radiotherapy (EBRT) <72 Gy (EBRT <72), EBRT ≥72 Gy (EBRT ≥72), combined seeds and EBRT (COMB), or radical prostatectomy (RP) for clinical Stage T1-T2 localized prostate cancer treated between 1990 and 1998.

  • radical prostatectomy External Beam Radiotherapy 72 gy External Beam Radiotherapy 72 gy permanent seed implantation or combined seeds External Beam Radiotherapy for stage t1 t2 prostate cancer
    International Journal of Radiation Oncology Biology Physics, 2002
    Co-Authors: Patrick A Kupelian, Louis Potters, Deepak Khuntia, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Thomas P Carlson, Eric A Klein
    Abstract:

    Abstract Purpose To review the biochemical relapse-free survival (bRFS) rates after treatment with permanent seed implantation (PI), External Beam Radiotherapy (EBRT) Methods and materials The study population comprised 2991 consecutive patients treated at the Cleveland Clinic Foundation or Memorial Sloan Kettering at Mercy Medical Center. All cases had pretreatment prostate-specific antigen (iPSA) levels and biopsy Gleason scores (bGSs). Neoadjuvant androgen deprivation for ≤6 months was given in 622 cases (21%). No adjuvant therapy was given after local therapy. RP was used for 1034 patients (35%), EBRT 0.2 for RP cases and three consecutive rising PSA levels (American Society for Therapeutic Radiology Oncology consensus definition) for all other cases. A multivariate analysis for factors affecting the bRFS rates was performed using the following variables: clinical T stage, iPSA, bGS, androgen deprivation, year of treatment, and treatment modality. The multivariate analysis was repeated excluding the EBRT Results The 5-year bRFS rate for RP, EBRT p p p p p p p p = 0.001) to be the only independent predictors of relapse. Treatment modality ( p = 0.95), clinical T stage ( p = 0.09), and androgen deprivation ( p = 0.56) were not independent predictors for failure. Conclusion The biochemical failure rates were similar among PI, high-dose (≥72 Gy) EBRT, COMB, and RP for localized prostate cancer. The outcomes were significantly worse for low-dose (

Patrick A Kupelian - One of the best experts on this subject based on the ideXlab platform.

  • monotherapy for stage t1 t2 prostate cancer radical prostatectomy External Beam Radiotherapy or permanent seed implantation
    Radiotherapy and Oncology, 2004
    Co-Authors: Louis Potters, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Eric A Klein, Michael W Kattan, Patrick A Kupelian
    Abstract:

    Abstract Background and Purpose To review the freedom from biochemical recurrence (FBR) rates after permanent prostate brachytherapy (PPB), External Beam Radiotherapy (RT) to a minimum 70Gy, or radical prostatectomy (RP) for clinically localized stage T1–T2 adenocarcinoma of the prostate. Patients and Methods The study cohort consisted of 1819 consecutively treated clinical stage T1–T2 (AJCC 1997) localized prostate cancer patients between 1992 and 1998. All patients received monotherapy treatment without additional adjuvant therapy. The distribution by treatment modality was as follows: RT for 340, RP for 746, and PPB for 733 cases. The median follow-up time was 58 months for all cases (51 months for PPB cases, 56 months for RT cases, and 64 months for RP cases). Biochemical relapse was defined as to be detectable PSA levels in RP cases, and the ASTRO consensus panel definition for the RT and PPB cases. Results The 7-year FBR rates for PPB vs EBRT vs RP were 74, 77, and 79%, respectively. Multivariate analysis identified iPSA ( P P Conclusions Pretreatment PSA levels, and biopsy Gleason score determined outcome in this study cohort. Biochemical failure rates in this study cohort are similar between PPB, RT, and RP as monotherapy for clinically localized prostate cancer.

  • clinical investigation prostateradical prostatectomy External Beam Radiotherapy 72 gy External Beam Radiotherapy 72 gy permanent seed implantation or combined seeds External Beam Radiotherapy for stage t1 t2 prostate cancer
    International Journal of Radiation Oncology Biology Physics, 2004
    Co-Authors: Patrick A Kupelian, Louis Potters, Deepak Khuntia, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Thomas P Carlson, Eric A Klein
    Abstract:

    Purpose To review the biochemical relapse-free survival (bRFS) rates after treatment with permanent seed implantation (PI), External Beam Radiotherapy (EBRT) <72 Gy (EBRT <72), EBRT ≥72 Gy (EBRT ≥72), combined seeds and EBRT (COMB), or radical prostatectomy (RP) for clinical Stage T1-T2 localized prostate cancer treated between 1990 and 1998.

  • radical prostatectomy External Beam Radiotherapy 72 gy External Beam Radiotherapy 72 gy permanent seed implantation or combined seeds External Beam Radiotherapy for stage t1 t2 prostate cancer
    International Journal of Radiation Oncology Biology Physics, 2002
    Co-Authors: Patrick A Kupelian, Louis Potters, Deepak Khuntia, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Thomas P Carlson, Eric A Klein
    Abstract:

    Abstract Purpose To review the biochemical relapse-free survival (bRFS) rates after treatment with permanent seed implantation (PI), External Beam Radiotherapy (EBRT) Methods and materials The study population comprised 2991 consecutive patients treated at the Cleveland Clinic Foundation or Memorial Sloan Kettering at Mercy Medical Center. All cases had pretreatment prostate-specific antigen (iPSA) levels and biopsy Gleason scores (bGSs). Neoadjuvant androgen deprivation for ≤6 months was given in 622 cases (21%). No adjuvant therapy was given after local therapy. RP was used for 1034 patients (35%), EBRT 0.2 for RP cases and three consecutive rising PSA levels (American Society for Therapeutic Radiology Oncology consensus definition) for all other cases. A multivariate analysis for factors affecting the bRFS rates was performed using the following variables: clinical T stage, iPSA, bGS, androgen deprivation, year of treatment, and treatment modality. The multivariate analysis was repeated excluding the EBRT Results The 5-year bRFS rate for RP, EBRT p p p p p p p p = 0.001) to be the only independent predictors of relapse. Treatment modality ( p = 0.95), clinical T stage ( p = 0.09), and androgen deprivation ( p = 0.56) were not independent predictors for failure. Conclusion The biochemical failure rates were similar among PI, high-dose (≥72 Gy) EBRT, COMB, and RP for localized prostate cancer. The outcomes were significantly worse for low-dose (

Louis Potters - One of the best experts on this subject based on the ideXlab platform.

  • monotherapy for stage t1 t2 prostate cancer radical prostatectomy External Beam Radiotherapy or permanent seed implantation
    Radiotherapy and Oncology, 2004
    Co-Authors: Louis Potters, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Eric A Klein, Michael W Kattan, Patrick A Kupelian
    Abstract:

    Abstract Background and Purpose To review the freedom from biochemical recurrence (FBR) rates after permanent prostate brachytherapy (PPB), External Beam Radiotherapy (RT) to a minimum 70Gy, or radical prostatectomy (RP) for clinically localized stage T1–T2 adenocarcinoma of the prostate. Patients and Methods The study cohort consisted of 1819 consecutively treated clinical stage T1–T2 (AJCC 1997) localized prostate cancer patients between 1992 and 1998. All patients received monotherapy treatment without additional adjuvant therapy. The distribution by treatment modality was as follows: RT for 340, RP for 746, and PPB for 733 cases. The median follow-up time was 58 months for all cases (51 months for PPB cases, 56 months for RT cases, and 64 months for RP cases). Biochemical relapse was defined as to be detectable PSA levels in RP cases, and the ASTRO consensus panel definition for the RT and PPB cases. Results The 7-year FBR rates for PPB vs EBRT vs RP were 74, 77, and 79%, respectively. Multivariate analysis identified iPSA ( P P Conclusions Pretreatment PSA levels, and biopsy Gleason score determined outcome in this study cohort. Biochemical failure rates in this study cohort are similar between PPB, RT, and RP as monotherapy for clinically localized prostate cancer.

  • clinical investigation prostateradical prostatectomy External Beam Radiotherapy 72 gy External Beam Radiotherapy 72 gy permanent seed implantation or combined seeds External Beam Radiotherapy for stage t1 t2 prostate cancer
    International Journal of Radiation Oncology Biology Physics, 2004
    Co-Authors: Patrick A Kupelian, Louis Potters, Deepak Khuntia, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Thomas P Carlson, Eric A Klein
    Abstract:

    Purpose To review the biochemical relapse-free survival (bRFS) rates after treatment with permanent seed implantation (PI), External Beam Radiotherapy (EBRT) <72 Gy (EBRT <72), EBRT ≥72 Gy (EBRT ≥72), combined seeds and EBRT (COMB), or radical prostatectomy (RP) for clinical Stage T1-T2 localized prostate cancer treated between 1990 and 1998.

  • radical prostatectomy External Beam Radiotherapy 72 gy External Beam Radiotherapy 72 gy permanent seed implantation or combined seeds External Beam Radiotherapy for stage t1 t2 prostate cancer
    International Journal of Radiation Oncology Biology Physics, 2002
    Co-Authors: Patrick A Kupelian, Louis Potters, Deepak Khuntia, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Thomas P Carlson, Eric A Klein
    Abstract:

    Abstract Purpose To review the biochemical relapse-free survival (bRFS) rates after treatment with permanent seed implantation (PI), External Beam Radiotherapy (EBRT) Methods and materials The study population comprised 2991 consecutive patients treated at the Cleveland Clinic Foundation or Memorial Sloan Kettering at Mercy Medical Center. All cases had pretreatment prostate-specific antigen (iPSA) levels and biopsy Gleason scores (bGSs). Neoadjuvant androgen deprivation for ≤6 months was given in 622 cases (21%). No adjuvant therapy was given after local therapy. RP was used for 1034 patients (35%), EBRT 0.2 for RP cases and three consecutive rising PSA levels (American Society for Therapeutic Radiology Oncology consensus definition) for all other cases. A multivariate analysis for factors affecting the bRFS rates was performed using the following variables: clinical T stage, iPSA, bGS, androgen deprivation, year of treatment, and treatment modality. The multivariate analysis was repeated excluding the EBRT Results The 5-year bRFS rate for RP, EBRT p p p p p p p p = 0.001) to be the only independent predictors of relapse. Treatment modality ( p = 0.95), clinical T stage ( p = 0.09), and androgen deprivation ( p = 0.56) were not independent predictors for failure. Conclusion The biochemical failure rates were similar among PI, high-dose (≥72 Gy) EBRT, COMB, and RP for localized prostate cancer. The outcomes were significantly worse for low-dose (

Wouter V Vogel - One of the best experts on this subject based on the ideXlab platform.

  • eanm snmmi practice guideline for 18f fdg pet ct External Beam Radiotherapy treatment planning in uterine cervical cancer v1 0
    European Journal of Nuclear Medicine and Molecular Imaging, 2021
    Co-Authors: Judit A Adam, Annika Loft, Cyrus Chargari, Roberto Delgado C Bolton, Elisabeth Kidd, Heiko Schoder, Patrick Veithaibach, Wouter V Vogel
    Abstract:

    The aim of this EANM / SNMMI Practice Guideline with ESTRO endorsement is to provide general information and specific considerations about [18F]FDG PET/CT in advanced uterine cervical cancer for External Beam Radiotherapy planning with emphasis on staging and target definition, mostly in FIGO stages IB3-IVA and IVB, treated with curative intention. Guidelines from related fields, relevant literature and leading experts have been consulted during the development of this guideline. As this field is rapidly evolving, this guideline cannot be seen as definitive, nor is it a summary of all existing protocols. Local variations should be taken into consideration when applying this guideline. The background, common clinical indications, qualifications and responsibilities of personnel, procedure / specifications of the examination, documentation / reporting and equipment specifications, quality control and radiation safety in imaging is discussed with an emphasis on the multidisciplinary approach.

  • eanm snmmi practice guideline for 18 f fdg pet ct External Beam Radiotherapy treatment planning in uterine cervical cancer v1 0
    European Journal of Nuclear Medicine and Molecular Imaging, 2021
    Co-Authors: Judit A Adam, Annika Loft, Cyrus Chargari, Roberto Delgado C Bolton, Elisabeth Kidd, Heiko Schoder, Patrick Veithaibach, Wouter V Vogel
    Abstract:

    The aim of this EANM / SNMMI Practice Guideline with ESTRO endorsement is to provide general information and specific considerations about [18F]FDG PET/CT in advanced uterine cervical cancer for External Beam Radiotherapy planning with emphasis on staging and target definition, mostly in FIGO stages IB3-IVA and IVB, treated with curative intention. Guidelines from related fields, relevant literature and leading experts have been consulted during the development of this guideline. As this field is rapidly evolving, this guideline cannot be seen as definitive, nor is it a summary of all existing protocols. Local variations should be taken into consideration when applying this guideline. The background, common clinical indications, qualifications and responsibilities of personnel, procedure / specifications of the examination, documentation / reporting and equipment specifications, quality control and radiation safety in imaging is discussed with an emphasis on the multidisciplinary approach.

Jay P Ciezki - One of the best experts on this subject based on the ideXlab platform.

  • monotherapy for stage t1 t2 prostate cancer radical prostatectomy External Beam Radiotherapy or permanent seed implantation
    Radiotherapy and Oncology, 2004
    Co-Authors: Louis Potters, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Eric A Klein, Michael W Kattan, Patrick A Kupelian
    Abstract:

    Abstract Background and Purpose To review the freedom from biochemical recurrence (FBR) rates after permanent prostate brachytherapy (PPB), External Beam Radiotherapy (RT) to a minimum 70Gy, or radical prostatectomy (RP) for clinically localized stage T1–T2 adenocarcinoma of the prostate. Patients and Methods The study cohort consisted of 1819 consecutively treated clinical stage T1–T2 (AJCC 1997) localized prostate cancer patients between 1992 and 1998. All patients received monotherapy treatment without additional adjuvant therapy. The distribution by treatment modality was as follows: RT for 340, RP for 746, and PPB for 733 cases. The median follow-up time was 58 months for all cases (51 months for PPB cases, 56 months for RT cases, and 64 months for RP cases). Biochemical relapse was defined as to be detectable PSA levels in RP cases, and the ASTRO consensus panel definition for the RT and PPB cases. Results The 7-year FBR rates for PPB vs EBRT vs RP were 74, 77, and 79%, respectively. Multivariate analysis identified iPSA ( P P Conclusions Pretreatment PSA levels, and biopsy Gleason score determined outcome in this study cohort. Biochemical failure rates in this study cohort are similar between PPB, RT, and RP as monotherapy for clinically localized prostate cancer.

  • clinical investigation prostateradical prostatectomy External Beam Radiotherapy 72 gy External Beam Radiotherapy 72 gy permanent seed implantation or combined seeds External Beam Radiotherapy for stage t1 t2 prostate cancer
    International Journal of Radiation Oncology Biology Physics, 2004
    Co-Authors: Patrick A Kupelian, Louis Potters, Deepak Khuntia, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Thomas P Carlson, Eric A Klein
    Abstract:

    Purpose To review the biochemical relapse-free survival (bRFS) rates after treatment with permanent seed implantation (PI), External Beam Radiotherapy (EBRT) <72 Gy (EBRT <72), EBRT ≥72 Gy (EBRT ≥72), combined seeds and EBRT (COMB), or radical prostatectomy (RP) for clinical Stage T1-T2 localized prostate cancer treated between 1990 and 1998.

  • radical prostatectomy External Beam Radiotherapy 72 gy External Beam Radiotherapy 72 gy permanent seed implantation or combined seeds External Beam Radiotherapy for stage t1 t2 prostate cancer
    International Journal of Radiation Oncology Biology Physics, 2002
    Co-Authors: Patrick A Kupelian, Louis Potters, Deepak Khuntia, Jay P Ciezki, C A Reddy, Alwyn M Reuther, Thomas P Carlson, Eric A Klein
    Abstract:

    Abstract Purpose To review the biochemical relapse-free survival (bRFS) rates after treatment with permanent seed implantation (PI), External Beam Radiotherapy (EBRT) Methods and materials The study population comprised 2991 consecutive patients treated at the Cleveland Clinic Foundation or Memorial Sloan Kettering at Mercy Medical Center. All cases had pretreatment prostate-specific antigen (iPSA) levels and biopsy Gleason scores (bGSs). Neoadjuvant androgen deprivation for ≤6 months was given in 622 cases (21%). No adjuvant therapy was given after local therapy. RP was used for 1034 patients (35%), EBRT 0.2 for RP cases and three consecutive rising PSA levels (American Society for Therapeutic Radiology Oncology consensus definition) for all other cases. A multivariate analysis for factors affecting the bRFS rates was performed using the following variables: clinical T stage, iPSA, bGS, androgen deprivation, year of treatment, and treatment modality. The multivariate analysis was repeated excluding the EBRT Results The 5-year bRFS rate for RP, EBRT p p p p p p p p = 0.001) to be the only independent predictors of relapse. Treatment modality ( p = 0.95), clinical T stage ( p = 0.09), and androgen deprivation ( p = 0.56) were not independent predictors for failure. Conclusion The biochemical failure rates were similar among PI, high-dose (≥72 Gy) EBRT, COMB, and RP for localized prostate cancer. The outcomes were significantly worse for low-dose (

Related terms

External Beam Radiotherapy - 15 days free trial to Access Experts & Abstracts